TY - JOUR
T1 - Feasibility of using optical coherence tomography to detect radiation-induced fibrosis and residual cancer extent after neoadjuvant chemo-radiation therapy
T2 - An ex vivo study
AU - Jelvehgaran, Pouya
AU - Alderliesten, Tanja
AU - Georgiou, Giota
AU - Meijer, Sybren L.
AU - Bloemen, Paul R.
AU - Kodach, Liudmila L.
AU - van Laarhoven, Hanneke W.M.
AU - van Berge Henegouwen, Mark I.
AU - Hulshof, Maarten C.C.M.
AU - Rasch, Coen R.N.
AU - van Leeuwen, Ton G.
AU - de Boer, Johannes F.
AU - de Bruin, Martijn
AU - van Herk, Marcel
PY - 2018/9/1
Y1 - 2018/9/1
N2 - Treatment of resectable esophageal cancer includes neoadjuvant chemo-radiation therapy (nCRT) followed by esophagectomy in operable patients. High-risk surgery may have been avoided in patients with a pathological complete response (pCR). We investigated the feasibility of optical coherence tomography (OCT) to detect residual cancer and radiation-induced fibrosis in 10 esophageal cancer patients that underwent nCRT followed by esophagectomy. We compared our OCT findings with histopathology. Overall, OCT was able to differentiate between healthy tissue, fibrotic tissue, and residual cancer with a sensitivity and specificity of 79% and 67%, respectively. Hence, OCT has the potential to add to the assessment of a pCR.
AB - Treatment of resectable esophageal cancer includes neoadjuvant chemo-radiation therapy (nCRT) followed by esophagectomy in operable patients. High-risk surgery may have been avoided in patients with a pathological complete response (pCR). We investigated the feasibility of optical coherence tomography (OCT) to detect residual cancer and radiation-induced fibrosis in 10 esophageal cancer patients that underwent nCRT followed by esophagectomy. We compared our OCT findings with histopathology. Overall, OCT was able to differentiate between healthy tissue, fibrotic tissue, and residual cancer with a sensitivity and specificity of 79% and 67%, respectively. Hence, OCT has the potential to add to the assessment of a pCR.
UR - http://www.scopus.com/inward/record.url?scp=85052748282&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85052748282&partnerID=8YFLogxK
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85052748282&origin=inward
U2 - https://doi.org/10.1364/BOE.9.004196
DO - https://doi.org/10.1364/BOE.9.004196
M3 - Article
C2 - 30615728
SN - 2156-7085
VL - 9
SP - 4196
EP - 4216
JO - Biomedical Optics Express
JF - Biomedical Optics Express
IS - 9
M1 - #330772
ER -
